S&P 500   4,270.13 (-0.32%)
DOW   33,678.00 (+0.31%)
QQQ   349.63 (-1.47%)
AAPL   178.33 (-0.49%)
MSFT   323.96 (-2.91%)
META   265.83 (-1.95%)
GOOGL   122.74 (-3.59%)
AMZN   121.50 (-4.04%)
TSLA   224.61 (+1.49%)
NVDA   377.09 (-2.44%)
NIO   7.83 (-0.63%)
BABA   85.45 (-1.44%)
AMD   118.40 (-4.69%)
T   15.99 (+2.04%)
F   13.50 (+4.41%)
MU   67.24 (-0.44%)
CGC   0.73 (-1.74%)
GE   105.89 (+0.41%)
DIS   92.52 (+0.39%)
AMC   4.74 (+2.16%)
PFE   38.88 (+1.33%)
PYPL   64.21 (-1.25%)
NFLX   401.37 (+0.52%)
S&P 500   4,270.13 (-0.32%)
DOW   33,678.00 (+0.31%)
QQQ   349.63 (-1.47%)
AAPL   178.33 (-0.49%)
MSFT   323.96 (-2.91%)
META   265.83 (-1.95%)
GOOGL   122.74 (-3.59%)
AMZN   121.50 (-4.04%)
TSLA   224.61 (+1.49%)
NVDA   377.09 (-2.44%)
NIO   7.83 (-0.63%)
BABA   85.45 (-1.44%)
AMD   118.40 (-4.69%)
T   15.99 (+2.04%)
F   13.50 (+4.41%)
MU   67.24 (-0.44%)
CGC   0.73 (-1.74%)
GE   105.89 (+0.41%)
DIS   92.52 (+0.39%)
AMC   4.74 (+2.16%)
PFE   38.88 (+1.33%)
PYPL   64.21 (-1.25%)
NFLX   401.37 (+0.52%)
S&P 500   4,270.13 (-0.32%)
DOW   33,678.00 (+0.31%)
QQQ   349.63 (-1.47%)
AAPL   178.33 (-0.49%)
MSFT   323.96 (-2.91%)
META   265.83 (-1.95%)
GOOGL   122.74 (-3.59%)
AMZN   121.50 (-4.04%)
TSLA   224.61 (+1.49%)
NVDA   377.09 (-2.44%)
NIO   7.83 (-0.63%)
BABA   85.45 (-1.44%)
AMD   118.40 (-4.69%)
T   15.99 (+2.04%)
F   13.50 (+4.41%)
MU   67.24 (-0.44%)
CGC   0.73 (-1.74%)
GE   105.89 (+0.41%)
DIS   92.52 (+0.39%)
AMC   4.74 (+2.16%)
PFE   38.88 (+1.33%)
PYPL   64.21 (-1.25%)
NFLX   401.37 (+0.52%)
S&P 500   4,270.13 (-0.32%)
DOW   33,678.00 (+0.31%)
QQQ   349.63 (-1.47%)
AAPL   178.33 (-0.49%)
MSFT   323.96 (-2.91%)
META   265.83 (-1.95%)
GOOGL   122.74 (-3.59%)
AMZN   121.50 (-4.04%)
TSLA   224.61 (+1.49%)
NVDA   377.09 (-2.44%)
NIO   7.83 (-0.63%)
BABA   85.45 (-1.44%)
AMD   118.40 (-4.69%)
T   15.99 (+2.04%)
F   13.50 (+4.41%)
MU   67.24 (-0.44%)
CGC   0.73 (-1.74%)
GE   105.89 (+0.41%)
DIS   92.52 (+0.39%)
AMC   4.74 (+2.16%)
PFE   38.88 (+1.33%)
PYPL   64.21 (-1.25%)
NFLX   401.37 (+0.52%)
NASDAQ:BLTE

Belite Bio (BLTE) News Today

$15.55
+0.45 (+2.98%)
(As of 02:57 PM ET)
Compare
Today's Range
$15.15
$15.89
50-Day Range
$15.10
$30.20
52-Week Range
$14.22
$44.70
Volume
18,151 shs
Average Volume
18,552 shs
Market Capitalization
$387.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$56.00
Get Belite Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter.



BLTE Media Mentions By Week

BLTE Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BLTE
News Sentiment

0.27

0.51

Average
Medical
News Sentiment

BLTE News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BLTE Articles
This Week

8

1

BLTE Articles
Average Week

SourceHeadline
marketbeat.com logoBelite Bio, Inc (NASDAQ:BLTE) to Post Q2 2023 Earnings of ($0.18) Per Share, HC Wainwright Forecasts
marketbeat.com - June 7 at 5:41 AM
MarketBeat logoHC Wainwright Cuts Belite Bio (NASDAQ:BLTE) Price Target to $55.00
americanbankingnews.com - June 5 at 11:24 AM
MarketBeat logoAnalyzing Belite Bio (NASDAQ:BLTE) and Cerevel Therapeutics (NASDAQ:CERE)
americanbankingnews.com - June 5 at 4:00 AM
finance.yahoo.com logoWhy Shares of Belite Bio Are Slumping Wednesday
finance.yahoo.com - May 31 at 4:53 PM
msn.com logoBelite Bio down 38%, prices $30M offering
msn.com - May 31 at 9:37 AM
marketwatch.com logoBelite Bio ADSs Plunge Premarket After Public Offering Priced >BLTE
marketwatch.com - May 31 at 9:37 AM
finance.yahoo.com logoBelite Bio Announces Pricing of $30 Million Underwritten Public Offering of American Depositary Shares and Warrants
finance.yahoo.com - May 31 at 12:00 AM
msn.com logoBelite Bio commences public offering of American Depositary Shares
msn.com - May 30 at 6:58 PM
finance.yahoo.com logoBelite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares and Warrants
finance.yahoo.com - May 30 at 6:58 PM
MarketBeat logoBelite Bio (NASDAQ:BLTE) Shares Gap Down to $24.02
americanbankingnews.com - May 25 at 7:32 AM
MarketBeat logoBelite Bio (NASDAQ:BLTE) Trading 4.6% Higher
americanbankingnews.com - May 19 at 6:40 AM
seekingalpha.com logoBelite Bio, Inc 2023 Q1 - Results - Earnings Call Presentation
seekingalpha.com - May 14 at 1:46 AM
finance.yahoo.com logoBelite Bio Reports First-Quarter 2023 Operational Highlights and Financial Results
finance.yahoo.com - May 11 at 12:23 AM
finance.yahoo.com logoBelite Bio to Host Webcast on May 11, 2023 to Discuss First Quarter 2023 Financial Results
finance.yahoo.com - May 10 at 7:22 PM
finance.yahoo.com logoBelite Bio to Host Key Opinion Leader Webinar Discussing Progression of Childhood-onset STGD1 and Relevance of the Tinlarebant 18-month Phase 2 Data
finance.yahoo.com - May 4 at 4:15 PM
MarketBeat logoBelite Bio, Inc (NASDAQ:BLTE) Short Interest Down 24.4% in March
americanbankingnews.com - April 17 at 8:54 AM
finance.yahoo.com logoBelite Bio to Host Key Opinion Leader Webinar on RBP4 Antagonist Tinlarebant in Late-Stage Development for Stargardt Disease 1
finance.yahoo.com - April 11 at 10:17 AM
finance.yahoo.com logoWe're Interested To See How Belite Bio (NASDAQ:BLTE) Uses Its Cash Hoard To Grow
finance.yahoo.com - April 8 at 1:02 PM
MarketBeat logoBelite Bio (NASDAQ:BLTE) Earns Buy Rating from HC Wainwright
americanbankingnews.com - April 6 at 3:40 AM
MarketBeat logoBelite Bio (NASDAQ:BLTE) Stock Rating Reaffirmed by Benchmark
americanbankingnews.com - April 6 at 3:40 AM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC) and Belite Bio, Inc. ADR (BLTE)
markets.businessinsider.com - April 4 at 7:43 AM
finance.yahoo.com logoBelite Bio Reports Full-Year 2022 Operational Highlights and Financial Results
finance.yahoo.com - March 31 at 9:09 PM
finance.yahoo.com logoBelite Bio to Host Webcast on April 3, 2023 to Discuss 2022 Full Year Financial Results
finance.yahoo.com - March 31 at 4:08 PM
MarketBeat logoBelite Bio (NASDAQ:BLTE) Sees Large Volume Increase
americanbankingnews.com - March 23 at 6:49 AM
wsj.com logoBelite Bio Inc. ADR
wsj.com - January 25 at 2:29 PM
marketbeat.com logoBelite Bio, Inc (NASDAQ:BLTE) Short Interest Update
marketbeat.com - January 2 at 9:19 AM
finance.yahoo.com logoBelite Bio to Host Key Opinion Leader Webinar on October 27, 2022 to discuss LBS-008 Interim Data
finance.yahoo.com - October 20 at 8:22 AM
marketbeat.com logoBelite Bio, Inc's (NASDAQ:BLTE) Lock-Up Period To End on October 26th
marketbeat.com - October 19 at 1:18 AM
marketbeat.com logoBelite Bio, Inc (NASDAQ:BLTE) Short Interest Down 5.5% in September
marketbeat.com - October 5 at 7:04 AM
marketbeat.com logoSmall-Cap Catalyst Pharma Is Among Market's Best Price Performers (BLTE)
marketbeat.com - October 3 at 6:25 PM
finance.yahoo.com logoBelite Bio Presented 12-Month Interim Results of LBS-008 Phase 1b/2 Study in Adolescent Stargardt Disease at AAO Annual Meeting 2022
finance.yahoo.com - October 1 at 11:49 PM
seekingalpha.com logoBelite Bio receives approval of begin LBS-008 phase 3 trial in China
seekingalpha.com - September 18 at 10:32 AM
marketbeat.com logoShort Interest in Belite Bio, Inc (NASDAQ:BLTE) Expands By 30.1%
marketbeat.com - September 17 at 4:08 AM
finance.yahoo.com logoBelite Bio Receives Approval of LBS-008 Phase 3 Clinical Trial in China
finance.yahoo.com - September 16 at 9:18 AM
marketbeat.com logoBelite Bio, Inc (NASDAQ:BLTE) Sees Large Increase in Short Interest
marketbeat.com - August 30 at 9:35 PM
seekingalpha.com logoBelite Bio adds 15% as pivotal trial for lead asset starts in U.S.
seekingalpha.com - August 23 at 9:19 PM
markets.businessinsider.com logoBelite Bio Shares Gain On Initiation Of Late-Stage Retinal Disease Study
markets.businessinsider.com - August 22 at 11:18 AM
marketbeat.com logoBelite Bio, Inc (NASDAQ:BLTE) Short Interest Down 9.2% in July
marketbeat.com - August 16 at 3:34 PM
seekingalpha.com logoBelite Bio, Inc's (BLTE) CEO Tom Lin on Q2 2022 Results - Earnings Call Transcript
seekingalpha.com - August 13 at 4:24 AM
nasdaq.com logoBelite Bio (NASDAQ:BLTE) Is In A Good Position To Deliver On Growth Plans
nasdaq.com - August 3 at 4:44 PM
finance.yahoo.com logo'Novel Approach For Retinal Disease Needs' Stock Belite Bio Has 70% Potential Upside According To This Analyst
finance.yahoo.com - August 1 at 6:41 PM
finance.yahoo.com logoBelite Bio to Host Conference Call on August 11, 2022 to Discuss First Half 2022 Financial Results
finance.yahoo.com - August 1 at 6:41 PM
finance.yahoo.com logoWe're Hopeful That Belite Bio (NASDAQ:BLTE) Will Use Its Cash Wisely
finance.yahoo.com - July 30 at 1:02 PM
marketbeat.com logo
marketbeat.com - July 20 at 10:01 AM
marketbeat.com logo
marketbeat.com - July 20 at 9:54 AM
marketbeat.com logo
marketbeat.com - July 20 at 9:50 AM
markets.businessinsider.com logoBelite Bio Seeks FDA Clearance For Late-Stage Genetic Eye Disease Study
markets.businessinsider.com - July 19 at 5:20 PM
finance.yahoo.com logoBelite Bio Submits Investigational New Drug (IND) Application to FDA for Approval to Proceed with LBS-008 Phase 3 Clinical Trial for the Treatment of Stargardt Disease
finance.yahoo.com - July 19 at 5:20 PM
benzinga.com logoBelite Bio (NASDAQ:BLTE), Analyst Ratings, Price Targets, Predictions
benzinga.com - July 3 at 4:38 AM
seekingalpha.com logoHot Stocks: META dips on curtailed hiring; PCT dips on CEO departure; ACCD earnings; BLTE gets Buy rating
seekingalpha.com - July 1 at 3:03 PM
Get Belite Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:BLTE) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -